Inflammation in Acute Cardiovascular Diseases - the CArdiovascular Inflammation Registry (CAIR)

Heart Failure Clinical Trial

— CAIR  

Official title:

An Observational-based Registry of Routinely Collected Clinical Parameters to Study Inflammation in Acute Cardiovascular Diseases - the CArdiovascular Inflammation Registry

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06411340
• Other study ID #: 334636
• Status: Not yet recruiting
• Start date: July 2024
• Est. completion date: July 2039

Study information

• Verified date: May 2024
• Source: King's College London
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

Following acute cardiovascular injury, inflammation is vital to activate reparative mechanisms. However, there is compelling evidence implicating excessive inflammation and dysregulated resolution in fibrosis, ventricular remodelling, and heart failure (HF). Recently, the anti-inflammatory agent colchicine reduced cardiovascular events after myocardial infarction (MI) compared to placebo, indicating that targeting inflammation in acute cardiovascular conditions is feasible. Several acute cardiovascular conditions are characterised by inflammation, including myocarditis, MI, and acute heart failure. However, there is large variability in definition, epidemiology, clinical presentation, pathophysiology, and natural history of acute inflammatory cardiovascular diseases. This relates, in part, to the difficulty in performing adequately powered studies. Clinical studies that include sufficient patients and extended observation periods are necessary to address some of these knowledge gaps. This registry aims to collate routinely collected clinical data on patients with acute cardiovascular diseases characterised by inflammation in an observational-based registry. By doing so, the investigators hope to understand the contribution of inflammation to the pathophysiology of acute cardiovascular disease, improve risk stratification, and identify potential novel therapeutic targets.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 1000
• Est. completion date: July 2039
• Est. primary completion date: July 2034
• Accepts healthy volunteers: No
• Gender: All
• Age group: 13 Years and older

Eligibility

Inclusion Criteria:

• Any patient 13 years of age or older with an acute cardiovascular condition requiring hospital admission is eligible.

Exclusion Criteria:

• <13 years of age

Related Conditions & MeSH terms

• Cardiovascular Diseases
• Heart Diseases
• Heart Failure
• Infarction
• Inflammation
• Myocardial Infarction
• Myocarditis
• Pericarditis

Intervention

Other:
• Observation
Observation

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
King's College London

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	All-cause mortality	Primary outcome will include all-cause mortality, but will vary by specific research project conducted within the registry.	1 year